The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer
{{output}}
Objective: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is effective in NSCLC patients with EGFR-activating or T790M mutations, but acquired resistance remains a major challenge. Although CCL2 has been im... ...
